Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling.

Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling.

Cabozantinib is an inhibitor of multiple receptor tyrosine kinases, including MET and VEGFR2. In a phase II clinical trial in advanced prostate cancer (PCa), cabozantinib treatment improved bone scans in 68% of evaluable patients. Our studies aimed to determine the expression of cabozantinib targets...

Full description

Bibliographic Details
Main Authors: Holly M Nguyen, Nazanin Ruppender, Xiaotun Zhang, Lisha G Brown, Ted S Gross, Colm Morrissey, Roman Gulati, Robert L Vessella, Frauke Schimmoller, Dana T Aftab, Eva Corey
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3808282?pdf=render

Internet

http://europepmc.org/articles/PMC3808282?pdf=render

Similar Items